Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2- intrahepatic cholangiocarcinoma,FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. In addition, the company offers SNAP platform which enable rapid structural design through iterative molecular SNAPshots. Tyra Biosciences, Inc. was incorporated in 2018 and is based in Carlsbad, California.

Tyra Biosciences, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CARLSBAD, CALIF., MAY 7, 2026 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, TODAY ANNOUNCED PARTICIPATION AT THE FOLLOWING INVESTOR CONFERENCES: BOFA SECURITIES HEALTH CARE CONFERENCE 2026 FORMAT: VIRTUAL FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGSPRESENTATION DATE/TIME:WEDNESDAY, MAY 13, 2026 AT 10:40 AM PTLOCATION: LAS VEGAS, NV TD COWEN'S 7TH ANNUAL ONCOLOGY INNOVATION SUMMIT: INSIGHTS FOR ASCO & EHA FORMAT: FIRESIDE CHAT WITH TYLER VAN BURENPRESENTATION DATE/TIME: TUESDAY, MAY 26, 2026 AT 2:00 PM ETLOCATION: VIRTUAL JEFFERIES GLOBAL HEALTHCARE CONFERENCE FORMAT: HYBRID FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGSPRESENTATION DATE/TIME: WEDNESDAY, JUNE 3, 2026 AT 3:45 PM ETLOCATION: NEW YORK, NY A LIVE WEBCAST OF THE PRESENTATIONS CAN BE ACCESSED BY VISITING THE "FOR INVESTORS" PAGE ON THE TYRA BIOSCIENCES WEBSITE AND WILL BE AVAILABLEFOR REPLAY FOLLOWING THE EVENT.

TYRA BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

-SEASONED BIOPHARMACEUTICAL LEADER BRINGS DEEP COMMERCIAL AND STRATEGIC EXPERTISE TO SUPPORT TYRA'S NEXT PHASE OF GROWTH- CARLSBAD, CALIF., APRIL 17, 2026 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, TODAY ANNOUNCED THE APPOINTMENT OF HABIB DABLE TO ITS BOARD OF DIRECTORS.

TYRA BIOSCIENCES ANNOUNCES APPOINTMENT OF HABIB DABLE TO ITS BOARD OF DIRECTORS

- LAUNCHED "DABOGRATINIB 3X3"STRATEGY TO PURSUE 3 LATE-STAGE CLINICAL STUDIES IN LG-UTUC, IR NMIBC AND ACH, 3 POTENTIAL BLOCKBUSTER INDICATIONS - - INTERIM PH2 DATA READOUTS ON TRACK: SURF302 EXPECTED BY END OF 1H'26 AND BEACH301 IN 2H '26 - - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $256.0 MILLION AT Q4 2025; RUNWAY THROUGH AT LEAST 2027 - CARLSBAD, CALIF., MARCH 2, 2026 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL-YEAR ENDED DECEMBER 31, 2025 AND HIGHLIGHTED RECENT CORPORATE PROGRESS.

TYRA BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2025 FINANCIAL RESULTS AND RECENT HIGHLIGHTS

CARLSBAD, CALIF., FEB. 23, 2026 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THAT TWO ABSTRACTS HAVE BEEN ACCEPTED FOR PRESENTATION AT THE 2026 ASCOGENITOURINARY(GU) CANCERS SYMPOSIUM (ASCO GU).

TYRA BIOSCIENCES ANNOUNCES POSTER PRESENTATIONS AT THE 2026 ASCO GENITOURINARY (GU) CANCERS SYMPOSIUM

CARLSBAD, CALIF., FEB. 19, 2026 /PRNEWSWIRE/ --TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, TODAY ANNOUNCED PARTICIPATION AT THE FOLLOWING INVESTOR CONFERENCES: 36TH ANNUAL OPPENHEIMER LIFE SCIENCES HEALTHCARE CONFERENCE FORMAT: VIRTUAL FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGSPRESENTATION DATE/TIME:THURSDAY, FEBRUARY 26, 2026 AT 12:00PM ETLOCATION: VIRTUAL 46TH ANNUAL TD COWEN HEALTHCARE CONFERENCE FORMAT: HYBRID PRESENTATION & FIRESIDE CHAT AND ONE-ON-ONE INVESTOR MEETINGSPRESENTATION DATE/TIME:WEDNESDAY, MARCH 4TH, 2026 AT 11:50AM ETLOCATION: BOSTON, MA LEERINK GLOBAL HEALTHCARE CONFERENCE FORMAT: ONE-ON-ONE INVESTOR MEETINGSDATE: MARCH 8-11, 2026LOCATION: MIAMI, FL 2026 JEFFERIES BIOTECH ON THE BEACH SUMMIT FORMAT: ONE-ON-ONE INVESTOR MEETINGSDATE: MARCH 9-11, 2026LOCATION: MIAMI, FL BARCLAYS 28TH ANNUAL GLOBAL HEALTHCARE CONFERENCE FORMAT: ONE-ON-ONE INVESTOR MEETINGSDATE: MARCH 10-12, 2026LOCATION: MIAMI, FL A LIVE WEBCAST OF THE PRESENTATIONS CAN BE ACCESSED BY VISITING THE "FOR INVESTORS" PAGE ON THETYRA BIOSCIENCES WEBSITE AND WILL BE AVAILABLEFOR REPLAY FOLLOWING THE EVENT.

CARLSBAD, CALIF. , DEC. 1, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THE APPOINTMENT OF TWO KEY MEMBERS OF ITS LEADERSHIP TEAM: BHAVESH ASHAR AS CHIEF OPERATING OFFICER AND HEATHER FAULDS AS CHIEF REGULATORY OFFICER.

TYRA BIOSCIENCES STRENGTHENS LEADERSHIP TEAM WITH APPOINTMENTS OF BHAVESH ASHAR AS CHIEF OPERATING OFFICER AND HEATHER FAULDS AS CHIEF REGULATORY OFFICER

CARLSBAD, CALIF. , NOV. 12, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THAT MEMBERS OF COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR EVENTS: JEFFERIES LONDON HEALTHCARE CONFERENCE FORMAT: HYBRID PRESENTATION (SLIDES & MODERATED Q&A) AND ONE-ON-ONE INVESTOR MEETINGSPRESENTATION DATE/TIME: WEDNESDAY, NOVEMBER 19, 2025, AT 4:00 PM GMT LOCATION: LONDON, UK 37TH ANNUAL PIPER HEALTHCARE CONFERENCE FORMAT: ONE-ON-ONE INVESTOR MEETINGSDATE: DECEMBER 2-4, 2025 LOCATION: NEW YORK, NY A LIVE WEBCAST OF THEJEFFERIES EVENT CAN BE ACCESSED BY VISITING THE "FOR INVESTORS" PAGE ON THETYRA BIOSCIENCES WEBSITE AND WILL BE AVAILABLE FOR REPLAY FOLLOWING THE EVENT.

TYRA BIOSCIENCES ANNOUNCES PARTICIPATION AT UPCOMING INVESTOR EVENTS

- DOSED FIRST PATIENTS WITH DABOGRATINIB IN BEACH301 AND SURF302; INTERIM RESULTS FROM BOTH STUDIES EXPECTED IN 2026 - - EXPANDED DEVELOPMENT OF DABOGRATINIB INTO LOW-GRADE UPPER TRACT UROTHELIAL CARCINOMA (LG-UTUC); IND CLEARED WITH U.S. FDA - - CASH, CASH EQUIVALENTS, AND MARKETABLE SECURITIES OF $274.9 MILLION AT Q3 2025; RUNWAY THROUGH AT LEAST 2027 - CARLSBAD, CALIF. , NOV. 5, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND HIGHLIGHTED RECENT CORPORATE PROGRESS.

TYRA BIOSCIENCES REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS

-DABOGRATINIB IS THE ONLY ORAL FGFR3-SELECTIVE INHIBITOR IN CLINICAL DEVELOPMENT FOR ACHONDROPLASIA- -INITIAL RESULTS FROM SAFETY SENTINEL COHORT EXPECTED IN 2H 2026- CARLSBAD, CALIF. , AUG. 21, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THAT THE FIRST CHILD HAS BEEN DOSED IN BEACH301, A PHASE 2 CLINICAL STUDY EVALUATING THE SAFETY AND EFFICACY OF DABOGRATINIB IN CHILDREN WITH ACHONDROPLASIA, THE MOST COMMON FORM OF DWARFISM.

TYRA BIOSCIENCES ANNOUNCES FIRST CHILD DOSED IN BEACH301, ITS PHASE 2 STUDY FOR DABOGRATINIB (TYRA-300) IN PEDIATRIC ACHONDROPLASIA

CARLSBAD, CALIF. , AUG. 20, 2025 /PRNEWSWIRE/ -- TYRA BIOSCIENCES, INC. (NASDAQ: TYRA), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING NEXT-GENERATION PRECISION MEDICINES THAT TARGET LARGE OPPORTUNITIES IN FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) BIOLOGY, ANNOUNCED TODAY THAT MEMBERS OF COMPANY MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR EVENTS:   VIRTUAL H.C.

Tyra Biosciences, Inc.

TYRA

Price

Financial Reports

No items found.

Press Releases

Tyra Biosciences, Inc.

TYRA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

TYRA